Therapeutic apoptotic cells for cancer therapy

An apoptotic cell, cancer technology, applied in the field of therapeutic apoptotic cells for cancer treatment, which can solve unmet and other problems

Pending Publication Date: 2020-04-10
ENLIVEX THERAPEUTICS LTD
View PDF23 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] There remains an unmet need for compositions and methods for treating, preventin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic apoptotic cells for cancer therapy
  • Therapeutic apoptotic cells for cancer therapy
  • Therapeutic apoptotic cells for cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0407] Example 1: Generation of apoptotic cells

[0408] Purpose: To generate early apoptotic cells.

[0409]Methods: Methods for preparing early apoptotic cell populations have been well documented in International Publication No. WO 2014 / 087408 and U.S. Application Publication No. US2015 / 0275175-A1, see, for example, "Preparation of Early Apoptotic Cell Populations" and "Apoptotic Cell Populations" Generation of Apoptotic Cells" Example preceding the "Methods" section (paragraph to ) and Examples 11, 12, 13 and 14, the entire contents of which are incorporated herein.

[0410] figure 1 The flow chart shown provides an overview of one embodiment of the steps used in the process of producing an early apoptotic cell population in which an anticoagulant is included in the thawing and induction of apoptosis steps. An early apoptotic cell population was prepared as described in Example 14 of International Publication No. WO2014 / 087408 and Example of U.S. Application Publication ...

Embodiment 2

[0461] Example 2: Effects of Apoptotic Cell Treatment on Non-Solid Tumor Models

[0462] Purpose: To test the effect of apoptotic cells on widespread cancer dissemination without localized or confined non-solid tumor models to determine the efficacy of apoptotic cells on cancer survival.

[0463] method:

[0464] Raji cells

[0465] Raji cells were purchased from ECACC (catalogue number: 85011429) and routinely cultured in complete medium (RPMI-1640 supplemented with 10% H.I.FBS, 1% Glutamax, 1% penicillin / streptomycin) and maintained at 3x10 5 –3x10 6 The concentration of cells / ml.

[0466] Apoptotic cells were prepared as described in Example 1. The resulting early apoptotic cells were at least 50% Annexin V positive and less than 5% PI positive.

[0467] Non-solid (diffuse) tumor models

[0468] On day 1 of the experiment, SCID mice received 10 5 A single IV injection of Raji cells. SCID mice in the control group received a single IV injection of saline solution. (...

Embodiment 3

[0479] Example 3: Effect of combined treatment of apoptotic cells and anti-CD20 mAb on diffuse tumor model

[0480] Objective: To test the effect of administering a combination of early apoptotic cells and an anti-CD20 mAb in a diffuse (non-solid) tumor model, where the cancer has spread widely and is not localized or confined, to determine the efficacy of this combination therapy on patient survival.

[0481] Raji cells, apoptotic cells, non-solid (diffuse) tumor models, solid tumor models and apoptotic cells were treated as described in Example 2 above.

[0482] anti-CD20 monoclonal antibody

[0483] A commercially available anti-CD20 mAb was purchased from Roche.

[0484] Anti-CD20 mAb treatment

[0485] Mice received an IV infusion of 5 mg anti-CD20 mAb.

[0486] Combined treatment of apoptotic cells and anti-CD20 mAb

[0487] Starting on day 6 after administration of Raji cells, mice received 3 IV infusions of 30x10 6 apoptotic cells. In addition, mice received an I...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of use of early apoptotic cell populations and compositions thereof disclosed herein include methods of treating a cancer or a tumor, extending survival times of a subject suffering from a cancer or a tumor, and reducing the size or reducing the growth rate of a cancer or a tumor, wherein subjects are administered apoptotic cells or compositions thereof. Cancers may include solid tumors ordiffuse cancers, for example leukemia. In certain instances compositions may include additional chemotherapeutic agent. Further, inactivated early apoptotic cell populations are disclosed and methodsof making the same.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 516,714, filed June 8, 2017, and U.S. Provisional Application No. 62 / 549,465, filed August 24, 2016, the entire contents of which are incorporated herein by reference. [0003] areas of interest [0004] Disclosed herein are compositions comprising populations of early apoptotic cells and methods for their use in cancer therapy. The compositions disclosed herein can be used to treat, prevent, inhibit the growth of, or reduce the incidence of, cancer or tumors in a subject. In addition, the compositions are useful for increasing the survival of subjects with cancer or tumors. The compositions used can be administered alone or in combination with other chemotherapy. Background technique [0005] Cancer is an abnormal state in which uncontrolled proliferation of one or more cell populations interferes with normal biological function. Proliferativ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/15A61K35/17C12N5/078A61P35/00
CPCA61K35/15A61K35/17A61P35/00C12N5/0634C07K16/2887A61K39/39533C07K16/2803C07K2319/03C07K2319/33C07K2317/622C12N2502/30C12N2502/99C12N2502/1114A61K39/0011A61K2039/5156A61K2039/5158C07K14/7051A61K2300/00A61K45/06C12N2529/10A61P35/02A61K9/0019A61K38/1774A61K39/3955A61K39/39558
Inventor S·诺维克D·梅沃拉克
Owner ENLIVEX THERAPEUTICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap